Pharmaceutical company AstraZeneca admits that there are side effects in its vaccine against Covid-19

The pharmaceutical multinational AstraZeneca admitted for the first time in court documents that its Covid vaccine “may cause rare side effects.”

The pharmaceutical giant revealed this information within the framework of a class action lawsuit that claims that the vaccine, developed with the University of Oxford, would have caused death and serious injuries in many cases.

The laboratory disputed those claims, although it acknowledged in a legal document presented to the Superior Court in February that its Covid vaccine “can, in very rare cases, ctousing TTS,” which is thrombosis syndrome with thrombocytopenia, causes people to have blood clots and a low blood platelet count.

The pharmacist stated that the vaccine can cause a fatal side effect of blood clotting, after facing a lawsuit against him, in which dozens of families allege that they, or their loved ones, were maimed or killed by the pharmaceutical titan’s “defective” vaccine.

This comes at the center of a multi-million pound class action lawsuit, which lawyers believe could net up to £20 million in compensation.

It is known as thrombosis with thrombocytopenia syndrome, a medical condition in which a person suffers from blood clots along with a low platelet count. Platelets often help blood clot.

Of the revelation, Kate Scott, Mr Scott’s wife, said: “I hope his admission means we can sort this out sooner rather than later.”

Furthermore, he added: “We need an apology and fair compensation for our family and other families who have been affected. “We have the truth on our side and we are not going to give up.”

It should be remembered that the vaccine, developed in collaboration with the University of Oxford, was acclaimed for its role in the United Kingdom’s fight against Covid, with more than 150 million doses administered to date.

Lawyers for victims and their families are suing AstraZeneca under the Consumer Protection Act of 1987, arguing that the vaccine was “a defective product” that “was not as safe as consumers generally had a right to expect.” . However, AstraZeneca has strongly denied these claims.

In that sense, health officials first identified cases of VITT linked to the AstraZeneca vaccine in Europe as early as March 2021, just over two months after the vaccine was first rolled out in the United Kingdom. However, it was only in April of that year that the evidence became clear enough for the vaccine to begin being restricted.

In the first instance, the authorities restricted the vaccine only to people over 30 years of age. Then, in May 2021, they expanded it to people over 40 years of age. As the vaccine still worked against Covid, it was still considered worth giving to older Britons who were at higher risk of death or injury from falling ill with the virus.

In total, around 50 million doses of the AstraZeneca vaccine have been distributed in the UK.